Research shows a unique T cell receptor repertoire in MIS-C patients

NewsGuard 100/100 Score

Children with coronavirus disease 2019 (COVID-19) sometimes develop the Multisystem Inflammatory Syndrome in Children (MIS-C), which is associated with high morbidity. The underlying T-cell associated mechanism is described by researchers in a new study published on the preprint server bioRxiv* in November 2020, as a response to superantigen activation.

Common superantigen-induced T Cell activation?

Toxic shock syndrome (TSS) and MIS-C share many similarities, with extensive and unregulated inflammation being characteristic of both. This study examined the occurrence of hyperinflammation in multiple body systems in children with COVID-19. These children experienced abdominal pain, diarrhea and rashes or had a weakening of the heart, sometimes involving cardiogenic shock. Strangely, these were not associated with severe respiratory symptoms. This suggests that MIS-C is due to extrapulmonary SARS-CoV-2 infection or a post-infectious inflammatory response.

TSS is also similar and is the result of superantigen stimulation, such as by Staphylococcal enterotoxin B (SEB). Superantigens are bacterial molecules that are very powerful at binding T cell receptors (TCR) and MHC class II molecules.

TCR V-beta skewing

The former binding engages specific beta-chains of the TCRs, involving their variable domains without having to rely on the complementary-determining region-3 (CDR3). This allows them to directly and nonspecifically activate the T cells and induce their proliferation, as well as elicit the unregulated hyperinflammatory cytokine-driven response (called a cytokine storm).

Specific superantigens bind to different TCR V-beta chains, and therefore T cells with these specific V-beta chains which bind to a diverse range of antigens will be overexpressed in these patients.

Complex Formation Between SARS-CoV-2 spike, TCR Containing Vβ11-2, and MHCII, and Comparative Analysis of TCR Vβ Sequences Homologous to Vβ11-2. (A) Binding of TCR (with Vβ chain sequentially identical to that of TRBV11-2 gene product) to the SAg-like region of SARS-CoV-2 spike. The TCR α- and β-chains are shown in magenta and cyan, respectively. The β-chain tightly binds the SAg-like region (E661 to R685; colored yellow). The spike subunits are colored dark red, beige, and gray; and the neurotoxin motif (299-356), green. (B-C) Ternary complex between spike, the same TCR and MHCII (green and the close-up view of the interfacial interactions between two basic residues, R682 and R683, on the SAg-like region of spike and the acidic residues (D67 and D68) of the TCR Vβ (D67 and D68) and TCRα.
Complex Formation Between SARS-CoV-2 spike, TCR Containing Vβ11-2, and MHCII, and Comparative Analysis of TCR Vβ Sequences Homologous to Vβ11-2. (A) Binding of TCR (with Vβ chain sequentially identical to that of TRBV11-2 gene product) to the SAg-like region of SARS-CoV-2 spike. The TCR α- and β-chains are shown in magenta and cyan, respectively. The β-chain tightly binds the SAg-like region (E661 to R685; colored yellow). The spike subunits are colored dark red, beige, and gray; and the neurotoxin motif (299-356), green. (B-C) Ternary complex between spike, the same TCR and MHCII (green and the close-up view of the interfacial interactions between two basic residues, R682 and R683, on the SAg-like region of spike and the acidic residues (D67 and D68) of the TCR Vβ (D67 and D68) and TCRα.

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Spike superantigen-like motif

The current study is based on the presence of a superantigen-like motif in the SARS-CoV-2 spike antigen. This binds to TCRs with high affinity as well as to MHC class II, forming a three-way complex. This motif closely resembles a staphylococcal superantigen in terms of sequence and structure. The TCR V-beta skewing seen in adults with severe hyperinflammatory COVID-19 phenotypes is similar to the type of immune response seen in superantigen-induced responses.

TCR beta variable gene expansion

The researchers explored the TCR range of expression in MIS-C with reference to V-beta skewing and signs of superantigen activation. They found that the TCR beta variable gene 11-2 (TRBV11-2) was greatly expanded. In mild MIS-C, there was a wider range of TCRs, just as in mild adult COVID-19, compared with severe MIS-C or COVID-19.

MIS-C patients showed an expansion of TRBV genes compared to patients with fever but without a SARS-CoV-2 infection. In severe disease, specific TRBV genes were exclusively over-represented, namely, TRBV11-2, TRBV24-1, and TRBV11-3 compared to either control with only fever or mild MIS-C patients.

The latter showed an expansion of TRBV-28 alone. Again, TRBV11-2 usage was correlated with the expression of inflammatory cytokines such as TNF-α, IFN-γ, IL-6 and IL-10 and with severe pediatric disease. This pattern was found to hold good irrespective of age in the severe MIS-C group.

Moreover, TRBV11-2 expansion correlated with PCR positivity rather than positive serology results. Over half the patients with this pattern were PCR positive, compared to zero patients without TRBV11-2 expansion. This data indicates an “association of TRBV11-2 expansion with active SARS-CoV-2 infection.”

Junctional diversity with TRBV11-2 expansion

Since CDR3 is not involved in superantigen interactions, the researchers expected a high degree of junctional diversity at the V(D)J junction in TCR with TRBV11-2 usage in severe MIS-C. This was confirmed by the finding that the CDR3/J genes in this subset of patients showed zero overlap, indicating high diversity. This again agrees with the canonical expansion profile observed with superantigen-induced activation.

TRAV8-4 was the most expanded gene among TRAVs in severe MIS-C patients, but no TRAV skewing was observed among mild MIS-C patients.

TRBV24-1 was overrepresented in adult patients with severe COVID-19, but less so in severe MIS-C. The single patient who had a robust expansion of the latter was a 15-year old.

Cytokine storm

TRBV11-2 expansion was correlated with the severity of MIS-C. Moreover, the serum cytokine levels in these patients agreed with those found in patients suffering from hyperimmune superantigen-triggered responses.  

Severe MIS-C is associated with a cytokine storm, which can cause autoimmune antibodies to be formed against endothelial, immune cells and myocardial cells among others, indicating a loss of B cell tolerance of self-antigens. Superantigens also affect T cell-B cell antigens via their binding to B cell MHC class II, promoting their differentiation into immunoglobulin secreting cells and the activation of both polyclonal and monoclonal B cells.

TRBV11-2 binds to the spike antigen

The researchers also carried out modeling studies which indicate a CDR3-independent engagement of the TRBV11-2 with a polybasic insert P681RRAR, within the superantigen-like motif found on the SARS-CoV-2 spike protein.

Implications

The study concludes, “These data suggest that SARS-CoV-2 spike may act as a superantigen to trigger the development of MIS-C as well as cytokine storm in adult COVID-19 patients, with important implications for the development of therapeutic approaches.” This could include anti-SEB antibodies – which are found in most people over 12, but at lower levels in those over the age of 70 – or drugs that prevent superantigen engagement by mimicking the peptide.

Further exploration will reveal the phenotypic and functional characterization of the T cells that use TRBV11-2 in these patients, shedding light on the mechanisms behind the disease manifestations.

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2020, November 11). Research shows a unique T cell receptor repertoire in MIS-C patients. News-Medical. Retrieved on April 30, 2024 from https://www.news-medical.net/news/20201111/Research-shows-a-unique-T-cell-receptor-repertoire-in-MIS-C-patients.aspx.

  • MLA

    Thomas, Liji. "Research shows a unique T cell receptor repertoire in MIS-C patients". News-Medical. 30 April 2024. <https://www.news-medical.net/news/20201111/Research-shows-a-unique-T-cell-receptor-repertoire-in-MIS-C-patients.aspx>.

  • Chicago

    Thomas, Liji. "Research shows a unique T cell receptor repertoire in MIS-C patients". News-Medical. https://www.news-medical.net/news/20201111/Research-shows-a-unique-T-cell-receptor-repertoire-in-MIS-C-patients.aspx. (accessed April 30, 2024).

  • Harvard

    Thomas, Liji. 2020. Research shows a unique T cell receptor repertoire in MIS-C patients. News-Medical, viewed 30 April 2024, https://www.news-medical.net/news/20201111/Research-shows-a-unique-T-cell-receptor-repertoire-in-MIS-C-patients.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights how age affects nasal cell response to SARS-CoV-2